Timothy Oostdyk - Eurofins Scientific Genomics BioPharma
| ERFSF Stock | USD 48.42 0.03 0.06% |
Insider
Timothy Oostdyk is Genomics BioPharma of Eurofins Scientific SE
| Phone | 352 26 18 53 20 |
| Web | https://www.eurofins.com |
Eurofins Scientific Management Efficiency
The company has return on total asset (ROA) of 0.075 % which means that it generated a profit of $0.075 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.1521 %, meaning that it generated $0.1521 on every $100 dollars invested by stockholders. Eurofins Scientific's management efficiency ratios could be used to measure how well Eurofins Scientific manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Jennifer Honeycutt | Danaher | 54 | |
| C Harris | Thermo Fisher Scientific | 64 | |
| Syed Jafry | Thermo Fisher Scientific | 56 | |
| Keeley Aleman | Waters | 47 | |
| Jeffery Chadbourne | IDEXX Laboratories | 48 | |
| Craig MD | Guardant Health | 57 | |
| Jonathan Pratt | Waters | 54 | |
| Kumud Kalia | Guardant Health | 58 | |
| Pearl Huang | Waters | 62 | |
| Otis Brawley | Agilent Technologies | 61 | |
| Jianqing Bennett | Waters | 54 | |
| Georgeann Couchara | Danaher | 47 | |
| Pardis Sabeti | Danaher | 45 | |
| Belinda Hyde | Waters | 53 | |
| Alexander MD | Illumina | 47 | |
| Andy Ament | Guardant Health | N/A | |
| Scott Ericksen | Illumina | 51 | |
| Gianluca Pettiti | Thermo Fisher Scientific | 45 | |
| Padraig McDonnell | Agilent Technologies | 49 | |
| Kevin Pegels | Illumina | 56 | |
| Allison Ballmer | Agilent Technologies | N/A | |
Management Performance
| Return On Equity | 0.15 | |||
| Return On Asset | 0.075 |
Eurofins Scientific Leadership Team
Elected by the shareholders, the Eurofins Scientific's board of directors comprises two types of representatives: Eurofins Scientific inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Eurofins. The board's role is to monitor Eurofins Scientific's management team and ensure that shareholders' interests are well served. Eurofins Scientific's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Eurofins Scientific's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Gilles Martin, Chairman and CEO | ||
| Yvoine Remy, VP Europe | ||
| Rajesh Saigal, Ex Asia | ||
| David Bryant, Sr America | ||
| Laurent Lebras, Group Director | ||
| Sandra Hoeylaerts, Chief Officer | ||
| Joachim Reichelt, VP Europe | ||
| Gabriel Julia, VP Europe | ||
| Valerie Hanote, Non-Executive Director | ||
| Timothy Oostdyk, Genomics BioPharma |
Eurofins Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Eurofins Scientific a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.15 | |||
| Return On Asset | 0.075 | |||
| Profit Margin | 0.1 % | |||
| Operating Margin | 0.17 % | |||
| Current Valuation | 15.96 B | |||
| Shares Outstanding | 192.56 M | |||
| Shares Owned By Insiders | 32.76 % | |||
| Shares Owned By Institutions | 36.56 % | |||
| Price To Earning | 21.61 X | |||
| Price To Book | 2.72 X |
Currently Active Assets on Macroaxis
Other Information on Investing in Eurofins Pink Sheet
Eurofins Scientific financial ratios help investors to determine whether Eurofins Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Eurofins with respect to the benefits of owning Eurofins Scientific security.